These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 26891424

  • 1. Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records.
    Warrer P, Thomsen PH, Dalsgaard S, Hansen EH, Aagaard L, Wallach Kildemoes H, Rasmussen HB.
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):354-61. PubMed ID: 26891424
    [Abstract] [Full Text] [Related]

  • 2. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

  • 3. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study.
    Søndergaard NR, Nørøxe KB, Carlsen AH, Randing SH, Warrer P, Thomsen PH, Clausen L.
    J Child Adolesc Psychopharmacol; 2024 Apr; 34(3):137-147. PubMed ID: 38608011
    [Abstract] [Full Text] [Related]

  • 4. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P, Sikirica V, Chen YJ, Curtice TG, Makin C.
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [Abstract] [Full Text] [Related]

  • 5. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
    Deng L, Zhou P, Zhu L, Zhang Y, Yang T, Zhao Q, Chen J, Li T, Cheng Q, Chen L.
    Pharmacol Biochem Behav; 2021 Sep; 208():173225. PubMed ID: 34217783
    [Abstract] [Full Text] [Related]

  • 6. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B, Karakaya E, Oztop DB.
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [Abstract] [Full Text] [Related]

  • 7. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC, Lee SY, Yuan SS, Yang CJ, Yang KC, Lee TL, Wang LJ.
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [Abstract] [Full Text] [Related]

  • 8. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting.
    Zhang Y, Yin L, You C, Liu C, Dong P, Xu X, Zhang K.
    Drugs R D; 2024 Mar; 24(1):29-39. PubMed ID: 37982991
    [Abstract] [Full Text] [Related]

  • 10. The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: A prospective study.
    Guvenmez O, Cubuk M, Gunes S.
    J Popul Ther Clin Pharmacol; 2020 May 01; 27(2):e45-e50. PubMed ID: 32379404
    [Abstract] [Full Text] [Related]

  • 11. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q, Zhang H, Fang Q, Qin L.
    J Clin Exp Neuropsychol; 2017 Nov 01; 39(9):854-865. PubMed ID: 28052720
    [Abstract] [Full Text] [Related]

  • 12. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.
    Health Technol Assess; 2006 Jul 01; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [Abstract] [Full Text] [Related]

  • 13. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T.
    J Child Adolesc Psychopharmacol; 2010 Feb 01; 20(1):55-61. PubMed ID: 20166797
    [Abstract] [Full Text] [Related]

  • 14. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC, Stein MA, Halperin JM, Krone B, Rajwan E, Newcorn JH.
    J Child Psychol Psychiatry; 2015 Jan 01; 56(1):40-8. PubMed ID: 24942409
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK, ADDUCE consortium.
    CNS Drugs; 2017 Mar 01; 31(3):199-215. PubMed ID: 28236285
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers.
    J Child Adolesc Psychopharmacol; 2012 Dec 01; 22(6):423-431. PubMed ID: 23362511
    [Abstract] [Full Text] [Related]

  • 17. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
    Yang L, Cao Q, Shuai L, Li H, Chan RC, Wang Y.
    Int J Neuropsychopharmacol; 2012 Feb 01; 15(1):15-26. PubMed ID: 22017969
    [Abstract] [Full Text] [Related]

  • 18. Differential long-term medication impact on executive function and delay aversion in ADHD.
    Rubio Morell B, Hernández Expósito S.
    Appl Neuropsychol Child; 2019 Feb 01; 8(2):140-157. PubMed ID: 29244542
    [Abstract] [Full Text] [Related]

  • 19. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.
    J Manag Care Pharm; 2007 Sep 01; 13(7):561-9. PubMed ID: 17874862
    [Abstract] [Full Text] [Related]

  • 20. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.
    Curr Med Res Opin; 2014 Aug 01; 30(8):1673-85. PubMed ID: 24627974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.